KR20090127273A - 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 - Google Patents
암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 Download PDFInfo
- Publication number
- KR20090127273A KR20090127273A KR1020097018554A KR20097018554A KR20090127273A KR 20090127273 A KR20090127273 A KR 20090127273A KR 1020097018554 A KR1020097018554 A KR 1020097018554A KR 20097018554 A KR20097018554 A KR 20097018554A KR 20090127273 A KR20090127273 A KR 20090127273A
- Authority
- KR
- South Korea
- Prior art keywords
- dna
- human
- treatment
- region
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims (19)
- WT1 특이적 세포 장해성 T 세포(CTL)의 T 세포 수용체(TCR)의 Vβ쇄의 CDR3을 코드하는 뉴클레오티드 배열을 가지며, 서열 번호: 1 내지 1695로 표시되는 임의의 CDR3 뉴클레오티드 배열을 갖는 DNA, 또는 그의 상보적 RNA, 또는 이들의 상보 배열을 갖는 폴리뉴클레오티드.
- 제1항에 있어서, 서열 번호: 1 내지 1695로 표시되는 임의의 CDR3 뉴클레오티드 배열을 포함하는 DNA, 또는 그의 상보적 RNA, 또는 이들의 상보 배열을 포함하는 폴리뉴클레오티드.
- WT1 특이적 세포 장해성 T 세포(CTL)의 T 세포 수용체(TCR)의 Vβ쇄의 CDR3의 아미노산 배열을 가지며, 서열 번호: 1696 내지 3389로 표시되는 임의의 CDR3 아미노산 배열을 갖는 펩티드.
- 제3항에 있어서, 서열 번호: 1696 내지 3389로 표시되는 임의의 CDR3 아미노산 배열을 포함하는 펩티드.
- 제1항 또는 제2항에 기재된 폴리뉴클레오티드 또는 제3항 또는 제4항에 기재된 펩티드의 암 마커로서의 사용.
- 치료 전에 HLA-A*2402 양성 환자로부터 얻어진 시료 중의, 제1항 또는 제2항에 기재된 임의의 폴리뉴클레오티드 또는 제3항 또는 제4항에 기재된 임의의 펩티드를 갖는 WT1 특이적 CTL의 클론형성능(clonality)을 조사하는 것을 특징으로 하며, 상기 클론형성능이 복수의 WT1 특이적 CTL이 존재하는 경우에 상기 환자가 암에 걸려 있을 가능성이 있다고 판정하는 암의 진단 방법.
- 제6항에 있어서, 치료 전의 환자에 있어서의 임의의 CDR3 폴리뉴클레오티드 또는 임의의 CDR3 펩티드를 갖는 3 이상의 클론형성능을 갖는 WT1 특이적 CTL의 클론형성능이 클수록, 또는 3 이상의 클론형성능을 갖는 WT1 특이적 CTL의 종류가 많을수록, 상기 환자가 암에 걸려 있을 가능성이 높다고 판정하는 방법.
- 치료 전에 있어서 HLA-A*2402 양성 환자로부터 얻어진 시료 중의, 제1항 또는 제2항에 기재된 임의의 폴리뉴클레오티드 또는 제3항 또는 제4항에 기재된 임의의 펩티드를 갖는 WT1 특이적 CTL의 종류 및 클론형성능을 조사하는 것을 특징으로 하는 WT1 펩티드 면역 요법에 대한 환자의 감수성을 조사하는 방법으로서, 상기 환자에 있어서의 클론형성능이 복수인 WT1 특이적 CTL의 종류가 WT1 펩티드 면역 요법에 대한 무응답자의 그것보다도 많은 경우에, WT1 펩티드 면역 요법에 대한 상기 환자의 감수성이 있다고 판정하는 방법.
- 제8항에 있어서, 치료 전의 환자에 있어서의 클론형성능이 복수인 WT1 특이적 CTL 클론의 종류가 많을수록, 또는 클론형성능이 클수록, WT1 펩티드 면역 요법에 대한 상기 환자의 감수성이 높다고 판정하는 방법.
- WT1 펩티드 면역 요법의 전후에 있어서, HLA-A*2402 양성 환자로부터 얻어진 시료 중의, 제1항 또는 제2항에 기재된 임의의 폴리뉴클레오티드 또는 제3항 또는 제4항에 기재된 임의의 펩티드를 갖는 WT1 특이적 CTL 클론의 클론형성능을 조사하는 것을 특징으로 하는 상기 환자에 있어서의 WT1 펩티드 면역 요법의 모니터링 방법으로서, 임의의 클론에 관해서 WT1 펩티드 면역 요법 전보다도 WT1 펩티드 면역 요법 후에 있어서 상기 WT1 특이적 CTL의 클론형성능이 증가한 경우에, 상기 환자가 WT1 펩티드 면역 요법에 응답했다고 판정하는 방법.
- 제10항에 있어서, WT1 펩티드 면역 요법 후에 있어서, 클론형성능의 증가 비율이 클수록, 또는 클론형성능이 증가한 클론의 종류가 많을수록, WT1 펩티드 면역 요법에 대한 응답성이 높다고 판정하는 방법.
- 제3항 또는 제4항에 기재된 펩티드에 대한 항체.
- 제1항 또는 제2항에 기재된 폴리뉴클레오티드, 제3항 또는 제4항에 기재된 펩티드, 또는 제12항에 기재된 항체를 포함하는 칩.
- 서열 번호: 3389 내지 3416로 표시되는 배열로부터 선택되는 배열을 갖는 CDR3 폴리펩티드 증폭용 프라이머.
- 제1항 또는 제2항에 기재된 폴리뉴클레오티드 또는 제3항 또는 제4항에 기재된 펩티드를 갖는 WT1 특이적 CTL을 검출하기 위한 수단을 포함하는 암의 진단 키트, WT1 펩티드 면역 요법에 대한 암환자의 감수성을 조사하기 위한 키트, 또는 WT1 펩티드 면역 요법의 모니터링용 키트.
- 제1항 또는 제2항에 기재된 폴리뉴클레오티드 또는 제3항 또는 제4항에 기재된 펩티드를 갖는 WT1 특이적 CTL을 검출하기 위한 수단을 포함하는 암의 진단 장치, WT1 펩티드 면역 요법에 대한 암환자의 감수성을 조사하기 위한 장치, 또는 WT1 펩티드 면역 요법의 모니터링용 장치.
- 제15항에 있어서, 제13항에 기재된 칩 또는 제14항에 기재된 프라이머를 포함하는 키트.
- 제16항에 있어서, 제13항에 기재된 칩 또는 제14항에 기재된 프라이머가 이 용되는 장치.
- 제1항 또는 제2항에 기재된 폴리뉴클레오티드 배열을 포함하는 T 세포 수용체 유전자를 도입한 HLA-A*2402 양성 암환자의 림프구.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007054215 | 2007-03-05 | ||
| JPJP-P-2007-054215 | 2007-03-05 | ||
| PCT/JP2008/053469 WO2008108257A1 (ja) | 2007-03-05 | 2008-02-28 | 癌抗原特異的t細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157023123A Division KR101773690B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090127273A true KR20090127273A (ko) | 2009-12-10 |
| KR101669279B1 KR101669279B1 (ko) | 2016-10-26 |
Family
ID=39738141
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157023123A Expired - Fee Related KR101773690B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| KR1020177023678A Expired - Fee Related KR101900639B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| KR1020097018554A Expired - Fee Related KR101669279B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157023123A Expired - Fee Related KR101773690B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| KR1020177023678A Expired - Fee Related KR101900639B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10093977B2 (ko) |
| EP (4) | EP2857508A3 (ko) |
| JP (3) | JP5808079B2 (ko) |
| KR (3) | KR101773690B1 (ko) |
| CN (2) | CN103374576A (ko) |
| AU (1) | AU2008222061B2 (ko) |
| BR (1) | BRPI0808341A2 (ko) |
| CA (1) | CA2679045A1 (ko) |
| MX (2) | MX343633B (ko) |
| TW (2) | TWI615469B (ko) |
| WO (1) | WO2008108257A1 (ko) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005001117A1 (ja) | 2003-06-27 | 2005-01-06 | Haruo Sugiyama | Wt1ワクチン適応患者の選択方法 |
| KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
| BRPI0808084A2 (pt) | 2007-02-27 | 2014-07-22 | Int Inst Cancer Immunology Inc | Método para ativação de células t auxiliadoras e composição para uso no método. |
| CN103864893B (zh) * | 2007-07-27 | 2017-01-04 | 伊玛提克斯生物技术有限公司 | 免疫疗法的免疫抗原表位 |
| GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| KR20140009168A (ko) | 2010-10-05 | 2014-01-22 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 헬퍼 t 세포의 활성화 방법 |
| CA2839663A1 (en) * | 2011-06-28 | 2013-01-03 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
| US9539299B2 (en) | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| US20150133342A1 (en) * | 2012-05-04 | 2015-05-14 | Nuclea Biotechnologies, Inc. | Mrm-ms signature assay |
| JP6163486B2 (ja) * | 2012-07-02 | 2017-07-12 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
| CA2884366A1 (en) * | 2012-09-12 | 2014-03-20 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper t-cell receptor genes |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| SG10201705028WA (en) | 2012-12-17 | 2017-07-28 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
| JP6250288B2 (ja) * | 2013-01-30 | 2017-12-20 | 株式会社医学生物学研究所 | T細胞レセプターおよびその利用 |
| EP2974734B1 (en) | 2013-03-12 | 2018-10-10 | Sumitomo Dainippon Pharma Co., Ltd. | Liquid aqueous composition |
| CN106170297A (zh) * | 2013-09-20 | 2016-11-30 | 纪念斯隆-凯特琳癌症中心 | 用于wt‑1‑阳性疾病的组合/辅助疗法 |
| US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
| KR20200138445A (ko) * | 2014-04-24 | 2020-12-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| EP3067366A1 (en) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| TWI726920B (zh) | 2015-10-14 | 2021-05-11 | 耶魯大學 | 基因體規模的t細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途 |
| RU2019116312A (ru) | 2016-11-14 | 2020-12-14 | Фред Хатчинсон Кэнсер Рисерч Сентер | Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性mage-a1特異的tcr及びその使用 |
| WO2018231958A1 (en) * | 2017-06-13 | 2018-12-20 | Adaptive Biotechnologies Corp. | Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs) |
| DE102017114737A1 (de) * | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| WO2019139972A1 (en) * | 2018-01-09 | 2019-07-18 | Board Of Regents, The University Of Texas System | T cell receptors for immunotherapy |
| US20220033774A1 (en) * | 2018-04-16 | 2022-02-03 | The Regents Of The University Of California | Compositions and methods for cytotoxic cd4+ t cells |
| WO2019222427A1 (en) * | 2018-05-16 | 2019-11-21 | Fred Hutchinson Cancer Research Center | Merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
| CN112469733B (zh) * | 2018-07-12 | 2022-04-19 | 深圳华大生命科学研究院 | Mart-1(27-35)表位特异性t细胞受体 |
| CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| CA3119188A1 (en) * | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | T cell receptors specific for mesothelin and their use in immunotherapy |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| WO2020257575A1 (en) * | 2019-06-21 | 2020-12-24 | St, Jude Children's Research Hospital | T-cell receptor for treating fibrolamellar hepatocellular carcinoma |
| US20220273714A1 (en) * | 2019-07-19 | 2022-09-01 | The Regents Of The University Of California | T-cell receptors and methods of use thereof |
| WO2021060343A1 (ja) * | 2019-09-24 | 2021-04-01 | オンコセラピー・サイエンス株式会社 | Urlc10由来ペプチドまたはdepdc1由来ペプチドを認識するヒトt細胞が発現するt細胞受容体 |
| WO2021217077A1 (en) * | 2020-04-24 | 2021-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Novel t-cell specificities and uses thereof |
| AU2021276264A1 (en) * | 2020-05-18 | 2022-12-22 | Board Of Regents, The University Of Texas System | Engineered T cell receptors and methods of use |
| CN111665359A (zh) * | 2020-07-11 | 2020-09-15 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
| CN113109564A (zh) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 |
| CN113092761A (zh) * | 2021-03-15 | 2021-07-09 | 成都益安博生物技术有限公司 | 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| EP4609202A2 (en) * | 2022-10-28 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof |
| CN120693174A (zh) * | 2022-12-13 | 2025-09-23 | 百欧恩泰美国公司 | T细胞受体构建体及其用途 |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923799A (en) | 1984-02-06 | 1990-05-08 | The Ontario Cancer Institute | T cell specific cDNA clone |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| JPH07504399A (ja) | 1991-08-28 | 1995-05-18 | ザ・ウィスター・インスティチュート | T細胞リセプターに基づいた慢性間接リウマチの治療法 |
| US5364787A (en) | 1992-03-23 | 1994-11-15 | Idaho Research Foundation | Genes and enzymes involved in the microbial degradation of pentachlorophenol |
| US20060134641A1 (en) * | 1992-05-22 | 2006-06-22 | Franklin Richard L | Treating viral infections with krill enzymes |
| US5494794A (en) * | 1992-10-20 | 1996-02-27 | Emory University | Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease |
| US5672509A (en) * | 1993-08-25 | 1997-09-30 | Pfizer Inc. | hPDE IV-C: a human phosphodiesterase IV isozyme |
| EP0846949B1 (en) | 1996-04-16 | 2005-06-29 | Kishimoto, Tadamitsu | Method of detecting solid cancer cells and histological heterotypia and method of examining tissue for bone marrow transplantation and peripheral blood stem cell transplantation |
| US5942422A (en) * | 1996-11-14 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Method for generating a directed, recombinant fusion nucleic acid |
| GB9710820D0 (en) | 1997-05-27 | 1997-07-23 | Univ Dundee | Immunological method |
| US6013444A (en) * | 1997-09-18 | 2000-01-11 | Oligotrail, Llc | DNA bracketing locus compatible standards for electrophoresis |
| AU5528198A (en) | 1997-12-03 | 1999-06-16 | Immune Response Corporation, The | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
| US6090593A (en) * | 1998-05-13 | 2000-07-18 | The United States Of America As Represented By The Secretary Of The Air Force | Isolation of expressed genes in microorganisms |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| AR021849A1 (es) | 1998-09-30 | 2002-08-07 | Corixa Corp | Composiciones y metodos para la inmunoterapia especifica de wt1 |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| DE60045188D1 (de) | 1999-02-23 | 2010-12-16 | Baylor College Medicine | T-ZELLREZEPTOR Vb-Db-Jb-SEQUENZ UND VERFAHREN FÜR IHREN NACHWEIS |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| EP1371664B1 (en) | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti modified peptide |
| ATE494905T1 (de) | 2001-06-29 | 2011-01-15 | Chugai Pharmaceutical Co Ltd | Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom |
| WO2003025569A1 (en) | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
| US20050002951A1 (en) | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| JP5230891B2 (ja) | 2001-09-28 | 2013-07-10 | 株式会社癌免疫研究所 | 抗原特異的t細胞の新規な誘導方法 |
| AU2003207528A1 (en) | 2002-01-09 | 2003-07-30 | Maxx Genetech Co. Ltd | Method of detecting t-cell proliferation for diagnosis of diseases by gene array |
| US7214492B1 (en) * | 2002-04-24 | 2007-05-08 | The University Of North Carolina At Greensboro | Nucleic acid arrays to monitor water and other ecosystems |
| WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
| WO2004024175A1 (ja) | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| WO2004063706A2 (en) * | 2003-01-08 | 2004-07-29 | Maxx Genetech Co., Ltd. | Method of detecting over-expression of t-cell receptor genes by real-time pcr |
| WO2005001117A1 (ja) * | 2003-06-27 | 2005-01-06 | Haruo Sugiyama | Wt1ワクチン適応患者の選択方法 |
| US20050191283A1 (en) * | 2003-10-16 | 2005-09-01 | Suzanne Kadereit | Methods of treating NFAT-related disorders |
| KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
| US20070238099A1 (en) | 2003-12-08 | 2007-10-11 | Cohen Irun R | Antigen Receptor Variable Region Typing |
| US7576183B2 (en) * | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| PT1731605E (pt) | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| GB0411771D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Nucleoproteins displaying native T cell receptor libraries |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| GB0427585D0 (en) | 2004-12-16 | 2005-01-19 | Avidex Ltd | Assay |
| WO2008026927A2 (en) | 2006-08-30 | 2008-03-06 | Academisch Medisch Centrum | Process for displaying t- and b-cell receptor repertoires |
| JP2009278927A (ja) | 2008-05-23 | 2009-12-03 | Tohoku Univ | T細胞受容体を模倣する抗体断片及びその製造方法 |
| CA2839663A1 (en) | 2011-06-28 | 2013-01-03 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
-
2008
- 2008-02-28 KR KR1020157023123A patent/KR101773690B1/ko not_active Expired - Fee Related
- 2008-02-28 MX MX2014010820A patent/MX343633B/es unknown
- 2008-02-28 CN CN2013102585890A patent/CN103374576A/zh active Pending
- 2008-02-28 KR KR1020177023678A patent/KR101900639B1/ko not_active Expired - Fee Related
- 2008-02-28 US US12/529,701 patent/US10093977B2/en not_active Expired - Fee Related
- 2008-02-28 WO PCT/JP2008/053469 patent/WO2008108257A1/ja not_active Ceased
- 2008-02-28 CA CA002679045A patent/CA2679045A1/en not_active Abandoned
- 2008-02-28 BR BRPI0808341-0A patent/BRPI0808341A2/pt not_active Application Discontinuation
- 2008-02-28 EP EP14192034.8A patent/EP2857508A3/en not_active Withdrawn
- 2008-02-28 EP EP16198218.6A patent/EP3173480A3/en not_active Withdrawn
- 2008-02-28 CN CN2008800134367A patent/CN101668853B/zh not_active Expired - Fee Related
- 2008-02-28 EP EP19150097.4A patent/EP3492590A3/en not_active Withdrawn
- 2008-02-28 KR KR1020097018554A patent/KR101669279B1/ko not_active Expired - Fee Related
- 2008-02-28 AU AU2008222061A patent/AU2008222061B2/en not_active Ceased
- 2008-02-28 JP JP2009502541A patent/JP5808079B2/ja not_active Expired - Fee Related
- 2008-02-28 EP EP08720964A patent/EP2116596A4/en not_active Withdrawn
- 2008-02-28 MX MX2009009589A patent/MX2009009589A/es active IP Right Grant
- 2008-03-04 TW TW097107430A patent/TWI615469B/zh not_active IP Right Cessation
- 2008-03-04 TW TW103145693A patent/TWI615470B/zh not_active IP Right Cessation
-
2014
- 2014-02-20 US US14/184,816 patent/US20140315758A1/en not_active Abandoned
- 2014-02-20 US US14/184,979 patent/US10669584B2/en not_active Expired - Fee Related
- 2014-03-20 JP JP2014058621A patent/JP5832572B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-30 JP JP2015151065A patent/JP6268129B2/ja not_active Expired - Fee Related
-
2020
- 2020-04-23 US US16/857,005 patent/US20210017599A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| Blood. Vol.95(1):286-293 (2000) * |
| Clinical Cancer Research Vol.11(24) Pt 1:8799-8807 (2005) * |
| Leukemia Research Vol.31(2):195-202 (온라인출판일 2006. 06. 05.) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101773690B1 (ko) | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 | |
| JP6483071B2 (ja) | ペプチド癌抗原特異的t細胞のレセプター遺伝子 | |
| AU2013270605B2 (en) | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them | |
| HK1198049A (en) | Receptor gene for peptide cancer antigen-specific t cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| J201 | Request for trial against refusal decision | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20191020 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20191020 |
